Head-to-head · WeighScore
Claya vs Kova
The verdict
Claya takes it — 62.8/100 to 44.3/100.
Claya grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Claya | Kova |
|---|---|---|
| WeighScore | 62.8/100 | 44.3/100 |
| Grade | C | C |
| Scorecard rank | #264 | #498 |
| Semaglutide | $299/mo (compounded) | Not disclosed |
| Tirzepatide | $299/mo (compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #264 · C
Strengths
- Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
- Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
- Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
- Weight-loss money-back guarantee published on the homepage
- Free expedited shipping included in the monthly price
Where it loses points
- States-served list not disclosed — you must check at checkout
- LegitScript certification status not displayed
- Corporate legal entity not disclosed on the site or privacy policy
- Oral compounded tablets have weaker efficacy data than injectable semaglutide
- Intro pricing is higher at refill ($299), erasing the first-month advantage
Graded #498 · C
Strengths
- Publishes the full price ladder for all three plan terms — intro month and renewal rate — directly in its FAQ
- Medication is included in the plan price, with no separate pharmacy charge
- States plainly that its compounded GLP-1s are 'not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality'
- Companion app tracks weight, protein and side effects, with medication schedule reminders
- You are not charged unless a provider approves treatment
Where it loses points
- At $449 per 4 weeks, the standing 1-month plan is among the most expensive compounded GLP-1 options we track
- The advertised $129 is the 6-month plan's intro month only — that plan then renews at $1,794 every 24 weeks
- Billed every 4 weeks rather than monthly, which is 13 charges a year instead of 12
- Never names which GLP-1 molecule is dispensed — only 'compounded, non-FDA-approved GLP-1 medications'
- No pharmacy or prescribing medical group is named anywhere on the site
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.